Summary

Eligibility
for people ages 18-99 (full criteria)
Location
at UCLA
Dates
study started
estimated completion
Principal Investigator
by Ken Herrmann (ucla)

Description

Summary

This pilot clinical trial studies fluordeoxyglucose (fludeoxyglucose) F-18 (FDG) positron emission tomography (PET)/computed tomography (CT) in monitoring very early therapy response in patients with glioblastoma. Diagnostic procedures, such as FDG PET/CT, may help measure a patient's response to earlier treatment. Chemotherapy can induce very rapid changes to the tumor's glucose consumption which can be measured with imaging. FDG PET/CT shortly after the start of therapy may help identify very early therapy response in patients with glioblastoma.

Official Title

Very Early Response Monitoring in Patients With Glioblastoma Undergoing Therapy Using FDG PET/CT

Details

PRIMARY OBJECTIVES:

  1. To assess very early response to therapy in glioblastoma patients using 18F-FDG PET/CT.

II. Evaluate very early changes in FDG uptake within 48 hours of start of therapy and correlate them with objective response parameters such as Response Assessment in Neuro-Oncology (RANO) and survival.

OUTLINE:

Patients undergo standard FDG PET/CT scan 6-8 weeks before start of chemotherapy and one additional FDG PET/CT scan within 48 hours of the start of chemotherapy.

Keywords

Glioblastoma FDG PET/CT very early response (48 hrs) Deoxyglucose Fluorodeoxyglucose F18 Computed Tomography Fludeoxyglucose F-18 Positron Emission Tomography

Eligibility

You can join if…

Open to people ages 18-99

  • Patients with histologically proven high grade glioma
  • Intention to start therapy

You CAN'T join if...

  • Severe psychiatric illness
  • Inability to give written consent
  • Breast feeding / pregnancy

Location

  • UCLA / Jonsson Comprehensive Cancer Center accepting new patients
    Los Angeles California 90095 United States

Lead Scientist at UC Health

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Jonsson Comprehensive Cancer Center
ID
NCT02902757
Study Type
Interventional
Last Updated